Table 1.
Biologics approved by the FDA in 2021 [5].
| Trade Name a | Active Ingredient a | Class | Indication |
|---|---|---|---|
| AdbryTM | Tralokinumab-ldrm | Monoclonal antibody | Atopic dermatitis |
| AduhelmTM | Aducanumab-avwa | Monoclonal antibody | Alzheimer’s disease |
| BesremiTM | Ropeginterferon alfa-2b-njft | Pegylated Protein | Polycythemia vera (overproduction of red blood cells) |
| EvkeezaTM | Evinacumab-dgnb | Monoclonal antibody | Homozygous familial hypercholesterolemia |
| JemperliTM | Dostarlimab-gxly | Monoclonal antibody | Endometrial cancer |
| NexviazymeTM | Avalglucosidase alfa-ngpt | Enzyme | Glycogen storage disease type II (Pompe disease) |
| RybrevantTM | Amivantamab-vmjw | Monoclonal antibody | Non-small cell lung cancer |
| RylazeTM | Asparaginase erwinia chrysanthemi (recombinant)-rywn | Enzyme | Acute lymphoblastic leukemia and lymphoma |
| SaphneloTM | Anifrolumab-fnia | Monoclonal antibody | Systemic lupus erythematosus |
| SkytrofaTM | Lonapegsomatropin-tcgd | Pegylated hormone | Growth hormone deficiency |
| Tezspire TM | Tezepelumab | Monoclonal antibody | Asthma as maintenance therapy |
| TivdakTM | Tisotumab vedotin-tftv | Antibody-drug conjugate | Cervical cancer |
| VyvgartTM | Efgartigimod alfa-fcab | Monoclonal antibody (fragment) | Myasthenia gravis |
| ZynlontaTM | Loncastuximab tesirine-lpyl | Antibody-drug conjugate | Relapsed or refractory large B-cell lymphoma |
a Trade name used in the USA.